Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 5.54% is 187% above its 5-year average of -6.39%, near the high end of its 5-year range (-63.79%–10.31%).
23.79% below its 12-month average of 7.27%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10.31%.
EBITDA MARGIN
5.54%
EBITDA MARGIN AVG TTM
7.27%
EBITDA MARGIN AVG 3Y
4.53%
EBITDA MARGIN AVG 5Y
-6.39%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-23.79%
CURRENT VS 3Y AVG
+22.28%
CURRENT VS 5Y AVG
+186.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
LifeStance Health Group, Inc.
Market Cap
$4.68B
EBITDA Margin
5.54%
TTM Avg
7.27%
3Y Avg
4.53%
5Y Avg
-6.39%
Market Cap
$4.66B
EBITDA Margin
7.23%
TTM Avg
7.47%
3Y Avg
7.86%
5Y Avg
7.54%
Market Cap
$4.70B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
Market Cap
$4.72B
EBITDA Margin
9.15%
TTM Avg
-7.04%
3Y Avg
-33.99%
5Y Avg
-33.99%
Market Cap
$4.79B
EBITDA Margin
-30.33%
TTM Avg
-1782.03%
3Y Avg
-5492.00%
5Y Avg
-5492.00%
Market Cap
$4.81B
EBITDA Margin
0.40%
TTM Avg
-9.29%
3Y Avg
-59.36%
5Y Avg
-227.69%
Market Cap
$4.42B
EBITDA Margin
-31.52%
TTM Avg
-36.86%
3Y Avg
-49.55%
5Y Avg
-49.55%
Market Cap
$4.40B
EBITDA Margin
23.00%
TTM Avg
14.06%
3Y Avg
2.00%
5Y Avg
2.94%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeStance Health Group, Inc. (LFST) | $4.68B | 5.54% | 7.27% | 4.53% | -6.39% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.66B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 7.23% | 7.47% | 7.86% | 7.54% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.70B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| BillionToOne, Inc. (BLLN)vs › | $4.72B | 9.15% | -7.04% | -33.99% | -33.99% |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.79B | -30.33% | -1782.03% | -5492.00% | -5492.00% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.81B | 0.40% | -9.29% | -59.36% | -227.69% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.42B | -31.52% | -36.86% | -49.55% | -49.55% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | 23.00% | 14.06% | 2.00% | 2.94% |
| Erasca, Inc. (ERAS)vs › | $4.96B | N/A | N/A | N/A | N/A |
Gross Margin
33.6%
EBITDA Margin
5.5%
Operating Margin
5.0%
Net Margin
3.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 10.31% |
| 2026-03-31 | 8.82% |
| 2025-12-31 | 8.25% |
| 2025-09-30 | 5.76% |
| 2025-06-30 | 3.20% |
| 2025-03-31 | 4.61% |
| 2024-12-31 | 4.83% |
| 2024-09-30 | 4.85% |
| 2024-06-30 | 0.85% |
| 2024-03-31 | 1.93% |
| 2023-12-31 | -3.58% |
| 2023-09-30 | -20.82% |
| 2023-06-30 | -11.13% |
| 2023-03-31 | -5.95% |
| 2022-12-31 | -11.83% |
| 2022-09-30 | -9.63% |
| 2022-06-30 | -20.87% |
| 2022-03-31 | -24.21% |
| 2021-12-31 | -51.79% |
| 2021-09-30 | -63.79% |
| 2021-06-30 | -21.35% |
| 2021-03-31 | 7.93% |
| 2020-12-31 | 12.96% |
| 2020-09-30 | 13.34% |
| 2020-06-30 | 12.18% |
| 2020-03-31 | 10.68% |
